GlobeNewswire·Sep 16, 2026, 8:30 AM ET

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Orchestra BioMed announced that its investigational AVIM Therapy will be featured in two sessions at the HRX Live 2026 conference in Atlanta from September 18-20, 2026.
A sponsored roundtable on Saturday, September 19, will focus on the collaboration between Orchestra BioMed and Medtronic to accelerate AVIM Therapy development for uncontrolled hypertension.
A second panel on Friday, September 18, will explore the expanding role of permanent cardiac pacing beyond bradycardia, including AVIM Therapy as a treatment for hypertensive heart disease.
The BACKBEAT Global Pivotal Trial, which evaluates AVIM Therapy for lowering blood pressure in pacemaker-indicated patients, is nearing enrollment completion.
Pilot studies demonstrated that AVIM Therapy achieved net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months.
AVIM Therapy has received FDA Breakthrough Device Designations for treating uncontrolled hypertension in patients with increased cardiovascular risk.
The therapy is compatible with standard dual-chamber pacemakers and targets approximately 7.7 million U.S. patients with uncontrolled hypertension despite medical therapy.
Orchestra BioMed also develops Virtue Sirolimus AngioInfusion Balloon, a drug delivery system for atherosclerotic artery disease that holds FDA Breakthrough Device Designations.